History of the cholesterol controversy in Britain

被引:10
作者
Thompson, G. R. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Invest Sci, Dept Metab Med, London W12 0NN, England
关键词
CORONARY-HEART-DISEASE; COENZYME-A REDUCTASE; PREVENTION; MEVINOLIN; INHIBITOR; COMPACTIN; EFFICACY; ML-236B; FATS;
D O I
10.1093/qjmed/hcn158
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The lipid hypothesis, the concept that cholesterol plays a causal role in atherosclerosis and cardiovascular disease, has been the subject of a controversy which started in the 1950s, peaked in the 1970s and 80s and then subsided in the 1990s. It was finally resolved by the positive outcome of the Scandinavian Simvastatin Survival Study, the first of 14 prevention trials using statins which showed that lowering cholesterol reduced both cardiovascular events and total mortality. This commentary focuses primarily on the events and people involved in the cholesterol controversy in Britain. The foremost critics of the lipid hypothesis are now deceased but unfortunately for many of the patients with hypercholesterolaemia and coronary heart disease it took the best part of 50 years to disprove the sceptics. This brief account relates why it took so long.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 50 条
  • [21] Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
    Alam, Uazman
    Al-Bazz, Dalal Y.
    Soran, Handrean
    [J]. DIABETES THERAPY, 2021, 12 (07) : 1779 - 1789
  • [22] Detection of 4a,5-dihydropravastatin as Impurity in the Cholesterol Lowering Drug Pravastatin
    van Scheppingen, Wibo B.
    Lankhorst, Peter P.
    Hans, Marcus
    van den Berg, Marco A.
    [J]. MOLECULES, 2021, 26 (15):
  • [23] Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
    Shah, Parth
    Glueck, Charles J.
    Goldenberg, Naila
    Min, Sarah
    Mahida, Chris
    Schlam, Ilana
    Rothschild, Matan
    Huda, Ali
    Wang, Ping
    [J]. LIPIDS IN HEALTH AND DISEASE, 2017, 16 : 1 - 12
  • [24] Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy
    Nichol, Kristin L.
    [J]. VACCINE, 2009, 27 (45) : 6305 - 6311
  • [25] HDL cholesterol and cardiovascular risk
    Ghali, William A.
    Rodondi, Nicolas
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338
  • [26] Cholesterol homeostasis and cardiovascular risk
    Weingaertner, O.
    Luetjohann, D.
    Boehm, M.
    Laufs, U.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (1-2) : 34 - 38
  • [27] Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
    Willeit, Peter
    Yeang, Calvin
    Moriarty, Patrick M.
    Tschiderer, Lena
    Varvel, Stephen A.
    McConnell, Joseph P.
    Tsimikas, Sotirios
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (23):
  • [28] Another Step Forward in Refining Risk Stratification Moving Past Low-Density Lipoprotein Cholesterol
    Milani, Richard V.
    Lavie, Carl J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (05) : 464 - 466
  • [29] More SPRINT controversy
    Messerli, F. H.
    Bangalore, S.
    Rimoldi, S. F.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2018, 283 (03) : 328 - 329
  • [30] Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Lowering With Atorvastatin in Patients of South Asian Compared With European Origin: Insights From the Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration (ACTFAST) Study
    Gupta, Milan
    Martineau, Pierre
    Thang Tran
    Despres, Jean-Pierre
    Gaw, Allan
    de Teresa, Eduardo
    Farsang, Csaba
    Gensini, Gian Franco
    Leiter, Lawrence A.
    Blanco-Colio, Luis Miguel
    Egido, Jesus
    Langer, Anatoly
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (06) : 850 - 858